Arden Trust’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Arden Trust’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-8,679	Closed	-$62K	–	823
2020 Q1	$62K	Buy	+8,679	New	+$108K	0.01%	450
2019 Q4	–	Sell	-7,589	Closed	-$204K	–	373
2019 Q3	$204K	Buy	+7,589	New	+$213K	0.03%	345
2019 Q2	–	Sell	-7,022	Closed	-$244K	–	387
2019 Q1	$244K	Buy	+7,022	New	+$203K	0.04%	321

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Arden Trust's PTLA Position: Q2 2020 in Review

Arden Trust sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 8,679 shares — an estimated $62K sold.

Arden Trust first reported a position in PTLA in Q1 2019 and held it in 3 quarters. The position peaked at $244K in Q1 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

Arden Trust reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Arden Trust sold 8,679 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $62K.
Arden Trust first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and held it in 3 quarters.
Arden Trust's Portola Pharmaceuticals, Inc. position peaked at $244K in Q1 2019.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Arden Trust's 13F filing for Q2 2020, filed 9 Jul 2020.